HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome

Nerea Hermida, Andreas Markl, Julien Hamelet, Tim Van Assche, Annelies Vanderper, Paul Herijgers, Marc van Bilsen, Denise Hilfiker-Kleiner, Gauthier Noppe, Christophe Beauloye, Sandrine Horman, Jean-Luc Balligand

Research output: Contribution to journalArticleAcademicpeer-review

27 Citations (Scopus)
Original languageEnglish
Pages (from-to)44-54
JournalCardiovascular Research
Volume99
Issue number1
DOIs
Publication statusPublished - 1 Jul 2013

Keywords

  • Myocardial fibrosis
  • Diastolic dysfunction
  • Metabolic syndrome
  • AMPK

Cite this

Hermida, N., Markl, A., Hamelet, J., Van Assche, T., Vanderper, A., Herijgers, P., van Bilsen, M., Hilfiker-Kleiner, D., Noppe, G., Beauloye, C., Horman, S., & Balligand, J-L. (2013). HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovascular Research, 99(1), 44-54. https://doi.org/10.1093/cvr/cvt070